News Release

Printer Friendly Version View printer-friendly version
<< Back

Zomedica Initiates ZM-006 Pilot Efficacy Study and Provides Corporate Updates

ANN ARBOR, Mich., March 05, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, initiated enrollment in its pilot efficacy study at the University of Georgia College of Veterinary Medicine to evaluate ZM-006, a transdermal methimazole formulation for the treatment of chronic hyperthyroidism in cats.

ZM-006 PILOT EFFICACY STUDY

The ZM-006 pilot efficacy study is being conducted to evaluate Zomedica’s transdermal methimazole formulation and, assuming positive study results, provide data for a future FDA Center for Veterinary Medicine (FDA-CVM) approved pivotal trial. Recognized as a center of excellence for endocrine diseases, the University of Georgia College of Veterinary Medicine is enrolling 12 newly diagnosed hyperthyroid cats and 12 hyperthyroid cats currently treated and controlled using oral methimazole. Enrolled patients will be treated with ZM-006 for three weeks with regular monitoring of clinical parameters including thyroid hormones.

“Our ZM-006 transdermal gel formulation is intended for application to the cat’s ear. Data obtained from this pilot efficacy study will help investigate an alternative treatment for hyperthyroid cats that may be less stressful for both owners and their feline companions,” stated Gerald Solensky Jr., Chairman and CEO at Zomedica.

Hyperthyroidism is one of the most commonly diagnosed endocrine disorders in middle-aged to older cats, occurring in about 10 percent of cats over 10 years of age, according to the American Association of Feline Practitioners. One method of treatment includes a FDA-CVM approved oral methimazole tablet. This can be problematic in that cats are notoriously difficult to pill. Although transdermal forms of methimazole are currently available from compounding pharmacies, they can have variable pharmaceutical efficacy and are not FDA-approved for use in veterinary medicine.

As previously disclosed, Zomedica expects to commence the pivotal safety study in the first half of 2019.

CORPORATE UPDATES

Zomedica also announced it will present at the H.C. Wainwright Global Life Sciences Conference April 7-9, 2019 in London, UK.

Investors and other interested parties will be able to access a live webcast of the presentation by visiting Zomedica’s website at http://investors.zomedica.com. A replay of the webcast will be accessible on the Zomedica website following the event.

As previously disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, which was filed with the Securities and Exchange Commission on February 26, 2019, Zomedica’s audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included a going concern explanatory paragraph. This announcement does not represent any change or amendment to Zomedica’s financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and pilot and pivotal studies, uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed in our filings with the Securities and Exchange Commission and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contacts
Shameze Rampertab, CPA, CA
srampertab@zomedica.com
+1 647.283.3630

PCG Advisory Group
Kirin Smith, COO
ksmith@pcgadvisory.com
+1 646.863.6519
www.pcgadvisory.com

Media Contact
Andrea Eberle
aeberle@zomedica.com
+1 734.369.2555

zomedica-horizontal-tag.jpg

Zomedica Pharmaceuticals Corp.